201741-17-5

Usage

Uses

Used in Pharmaceutical Industry:
(4-Hydroxy-2-methylphenyl)carbamic acid tert-butyl ester is used as a drug intermediate for the development of anticonvulsant and antiepileptic drugs. Its potential use in treating seizure disorders and epilepsy has been extensively studied.
Used in Pesticide Industry:
(4-Hydroxy-2-methylphenyl)carbamic acid tert-butyl ester is used as a pesticide due to its pesticidal properties. It helps in controlling and managing pests in agricultural settings.
Used in Organic Synthesis:
(4-Hydroxy-2-methylphenyl)carbamic acid tert-butyl ester is used as a protecting group for carbamic acid in organic synthesis. The tert-butyl ester group provides stability, making it useful in various chemical reactions and pharmaceutical research.

InChI:InChI=1/C12H17NO3/c1-8-7-9(14)5-6-10(8)13-11(15)16-12(2,3)4/h5-7,14H,1-4H3,(H,13,15)

Upstream product

• 1095280-74-2 N-Boc-N-(2-methylphenyl)-O-(4-nitrobenzoyl)hydroxylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2835-99-6 4-amino-3-methylphenol 

Downstream Products

• 700835-82-1 tert-butyl 4-{[3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl]methoxy}-2-methylphenylcarbamate 

Relevant academic research and scientific papers

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

CYCLIC AMIDE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (1): (where n is 0 to 2; p is 0 to 4; h is 0 to 3; j is 0 to 3; k is 0 to 2; a ring B is an aryl group or a heteroaryl group; X is O, S, or —NR7—; J1 is —CR11aR11b— or —NR11c—; J2 is —CR12aR12b— or —NR12c—; and R1 to R12c are specific groups), a salt of the compound, or a solvate of the salt or the compound.

Rearrangement of differentially protected N-arylhydroxylamines

The rearrangement of a series of N,O-difunctionalised N-arylhydroxylamines to generate protected 2-aminophenols has been investigated. N-Boc-N-Aryl-O- acylhydroxylamines are stable, isolable compounds which rearrange smoothly at temperatures between 110 and 140°C. The corresponding N-Boc-N-aryl-O- sulfonylhydroxylamines were not isolated and rearrange to 1,2-difunctionalised aminophenols at room temperature in excellent yield. Deprotection of either the N- or O-substituents under standard conditions allows for further synthetic manipulation of either the aniline or phenol functionality. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

FARNESOID X RECEPTOR AGONISTS

The invention relates to a compound of formula (I) useful as an agonist for FXR: wherein all variables are as defined herein and to pharmaceutical compositions, methods of using, and processes for preparing the same.

Fibrinogen receptor antagonist prodrugs

Fibrinogen receptor antagonist alcohol prodrugs having the structure, for example, of more particularly, STR1